C
VRDN icon

Covestor’s Viridian Therapeutics VRDN Stock Holding History

Covestor’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1K Buy
29
+24
+480% +$387 ﹤0.01% 2380
2026
Q1 		$0 Hold
5
– – ﹤0.01% 2815
2025
Q4 		$0 Hold
5
– – ﹤0.01% 2782
2025
Q3 		$0 Hold
5
– – ﹤0.01% 2823
2025
Q2 		$0 Hold
5
– – ﹤0.01% 2802
2025
Q1 		$0 Hold
5
– – ﹤0.01% 2770
2024
Q4 		$0 Sell
5
-2
-29% -$43 ﹤0.01% 2787
2024
Q3 		$0 Sell
7
-1
-13% -$16 ﹤0.01% 2816
2024
Q2 		$0 Buy
8
+4
+100% +$55 ﹤0.01% 2804
2024
Q1 		$0 Sell
4
-1
-20% -$19 ﹤0.01% 2791
2023
Q4 		$0 Hold
5
– – ﹤0.01% 2770
2023
Q3 		$0 Buy
5
+2
+67% +$38 ﹤0.01% 2763
2023
Q2 		$0 Hold
3
– – ﹤0.01% 2700
2023
Q1 		$0 Buy
+3
New +$96 ﹤0.01% 2634

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Covestor's VRDN Position: Q2 2026 in Review

Covestor increased its Viridian Therapeutics (VRDN) stake by 480% in Q2 2026, buying an estimated $387 and bringing the position to 29 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2380.

Covestor first reported a position in VRDN in Q1 2023 and has held it in 14 quarters since. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Covestor held 29 shares of Viridian Therapeutics worth $1K as of Q2 2026.
  • Covestor bought 24 Viridian Therapeutics shares in Q2 2026, an estimated $387.
  • Viridian Therapeutics made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2380 holding.
  • Covestor first reported a position in Viridian Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.